COMMUNIQUÉS West-GlobeNewswire

Privia Health to Report Fourth Quarter 2025 Results on Thursday, February 26
22/01/2026
ARLINGTON, Va., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its fourth-quarter and twelve-month periods ended December 31, [...]
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
22/01/2026
Patent Enhances IP Estate for Lead Asset; Combined with Anticipated Biologics Exclusivity, Market Protections Extend Over 20 Years PRINCETON, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq [...]
Cannabix Marijuana Breath Test Featured on the Cover of AlcoPro’s 2026 Product Catalog
22/01/2026
VANCOUVER, British Columbia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) a developer of marijuana and alcohol breath-testing [...]
NetraMark Engages LodeRock Advisors for Strategic Investor Relations and Capital Markets Communications Services
22/01/2026
TORONTO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials [...]
NARMAFOTINIB Large-Scale Manufactre Complete
22/01/2026
Successful completion of the first large-scale manufacture of narmafotinib which produced approx. 13 kg of drug Successful transition of process and production from an R&D facility to a commercial manufacturing [...]
What Are the Top Customer Experience Trends for 2026? New Transcom Report Identifies Five Paradoxes CX Leaders Must Address
22/01/2026
Report explains how enterprises should use AI, automation, and human expertise together to close the Experience Gap Denver CO., Jan. 22, 2026 (GLOBE NEWSWIRE) -- As enterprises evaluate how artificial intelligence will [...]
Kaida BioPharma Appoints Co-Founder Dr. Stella K. Vnook as Chairperson of the Board
22/01/2026
Appointment aligns Board leadership with Company’s transition to clinical-stage development and advancement of KAD-101 for platinum-resistant ovarian cancer Company advancing KAD-101, a best-in-class, next-generation [...]
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention
22/01/2026
The educational campaign will focus on teaching the American public about antibodies and preventing infectious disease The collaboration will advance public understanding of antibodies as a centerpiece of modern [...]
NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board
22/01/2026
Dr. Miller’s appointment further enhances NKGen’s scientific and clinical advisory capabilities as the Company advances its research in Alzheimer’s and other related neurodegenerative diseases SANTA ANA, Calif., Jan. 22 [...]
60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention
22/01/2026
Partnership adds a travel-focused consumer telehealth platform to the ARAKODA ® marketing strategy, offering a new convenience to people planning travel to malaria-endemic regions of the world ARAKODA is the only FDA- [...]
Catheter Precision Receives First Purchase Order for LockeT in Germany
22/01/2026
FORT MILL, S.C., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac [...]
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
22/01/2026
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that [...]
CORXEL Announces $287 million Series D1 Financing to Further Advance Its Cardiometabolic Pipeline including Oral Small Molecule GLP-1 Receptor Agonist
22/01/2026
Series D1 financing with participation from a syndicate of global healthcare-focused investors, including RTW Investments, SR One Capital Management (SR One), TCG Crossover (TCGX), RA Capital Management, HBM Healthcare [...]
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
22/01/2026
CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide [...]
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization
22/01/2026
Expands CNSide Clinical License in State of Pennsylvania HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision [...]
Tilray Medical Strengthens Italian Market Presence with the Launch of Tilray Medical Italia and Expanded Medical Cannabis Portfolio
22/01/2026
NEW YORK and SAVONA, Italy, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic [...]
Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development U.S.
22/01/2026
LAUPHEIM, Germany and MILFORD, Mass., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that [...]
Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
22/01/2026
Amendment reduces and simplifies royalty structure on Teverelix ® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix ® as a first in class market product for Acute Urinary [...]
Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01
22/01/2026
STAFFORD, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]

Pages